市場調查報告書
商品編碼
1470568
肝病診斷市場:按診斷技術和最終用戶分類 - 全球預測 2024-2030Liver Disease Diagnostics Market by Diagnosis Technique (Biopsy, Endoscopy, Imaging), End-user (Hospitals, Laboratories) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年肝病診斷市場規模為99.4億美元,預計2024年將達110.9億美元,2030年將達到230.5億美元,複合年成長率為12.76%。
肝病診斷市場包括專門用於檢測和監測各種肝病(如肝炎、肝硬化、肝癌和非酒精性脂肪肝)的所有技術、產品和服務。主要目標是促進肝臟相關疾病的早期發現、準確分期和有效管理。肝病盛行率不斷上升,人們的認知和預防方法不斷提高,以及各地區醫療基礎設施的改善,使得肝病診斷解決方案的採用成為必要。此外,政府對肝病監測和管理的努力和資助正在增加對肝病診斷的需求。然而,肝病診斷面臨挑戰,例如先進診斷測試成本高、肝病診斷標準不一致以及資源匱乏地區的獲取機會有限。此外,缺乏某些肝臟疾病的特異性生物標記以及與侵入性診斷程序相關的風險可能會阻礙生長。然而,主要參與者正在探索非侵入性成像技術和生物標記發現等尖端發展,以避免技術和安全併發症。此外,人工智慧和機器學習在診斷中的日益整合,有望提高準確性和預測分析能力,也開闢了新的成長途徑。個人化醫療和基因組學也越來越受到關注,為客製化診斷和治療方法提供了潛力。
主要市場統計 | |
---|---|
基準年[2023] | 99.4億美元 |
預測年份 [2024] | 110.9億美元 |
預測年份 [2030] | 230.5億美元 |
複合年成長率(%) | 12.76% |
診斷技術:診斷肝臟疾病的影像方法不斷進步
肝臟切片檢查是取出一小部分肝組織並在顯微鏡下觀察的過程。切片檢查對於診斷某些血液檢查或影像學檢查無法檢測到的肝臟疾病以及確定肝損傷的程度非常重要。當需要分析C型肝炎等慢性疾病造成的肝損傷程度,或需要診斷原因不明的肝臟異常時,通常會建議進行切片檢查。用於肝臟診斷的內視鏡檢查通常是指稱為內視鏡逆行性造影的手術,用於檢查膽管。它可以識別與膽管阻塞和肝臟疾病相關的異常。當醫生懷疑有影響膽管的疾病或需要移除膽管結石時,通常會進行內視鏡檢查。診斷影像,包括超音波、電腦斷層掃描和磁振造影,可以提供肝臟的詳細影像,有助於診斷脂肪肝、腫瘤和肝硬化等疾病。診斷影像是一種第一線非侵入性診斷技術,通常在需要目視評估肝臟結構和檢測腫塊時使用。實驗室檢查可以透過分析血液樣本來幫助診斷肝病。常見的測試包括肝酵素測試,如丙氨酸轉氨酶(ALT)測試和天門冬胺基轉移酶(AST)測試、膽紅素測試、白蛋白測試、血液凝固檢查和病毒性肝炎測試。實驗室檢查通常是診斷肝病的第一步,用於常規篩檢、監測疾病進展和評估治療效果。
最終用戶在政府措施的支持下進行全球醫院擴張,以發展強大的醫療保健基礎設施
醫院是肝病診斷的重要最終使用者。醫院通常擁有先進的診斷設備,並配備專門的醫療保健專業人員。肝病患者通常需要立即進行綜合治療,而醫院通常能夠提供這些治療。這包括一系列診斷測試,如血液測試、影像和切片檢查,以確認肝炎、肝硬化和肝癌等診斷。醫院通常根據需求而受到高度青睞,因為它們能夠提供從診斷到治療的一體化服務,包括緊急醫療護理、手術和術後追蹤。診斷服務與治療的結合是病人選擇醫院診斷的一個令人信服的理由。實驗室,無論是獨立的還是附屬於診所的,都專門分析血液和組織樣本以檢測肝臟異常。與醫院相比,檢測設施位置便利,診斷檢測所需時間更短。該實驗室主要滿足診斷和監測肝病所需的常規篩檢和血液檢測的需要。
區域洞察
架構地區以美國和加拿大為中心,具有強大的醫療保健結構和對各種疾病有利的報銷政策,促進了肝病診斷的發展。非侵入性成像技術和生物標記識別領域的創新正在獲得大量投資和專利申請。美國肝臟基金會為改善肝臟健康所做的努力等措施反映了該領域的積極努力。歐盟(EU)根據其成員國的不同,擁有不同的醫療保健系統和經濟實力,因此消費者行為也多種多樣。然而,歐洲肝臟研究協會臨床實踐指南的採用是肝臟疾病診斷標準化的重要因素。不斷增加的研發支出和多邊合作(例如歐盟的地平線 2020 計畫)展現了該地區充滿活力的創新環境。在亞太地區,由於肝臟相關疾病的盛行率不斷增加、人們對肝臟健康的認知不斷提高,以及政府努力將醫療設施擴展到馬蘇,因此對肝臟疾病診斷的需求正在迅速增加。此外,亞太地區擴大採用數位醫療服務和解決方案,這可以為該行業提供新的成長途徑。
FPNV定位矩陣
FPNV定位矩陣對於評估肝病診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對肝病診斷市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.肝病診斷市場的市場規模與預測是多少?
2.肝病診斷市場預測期內需要考慮投資的產品、細分市場、應用及領域有哪些?
3.肝病診斷市場的技術趨勢與法規結構是什麼?
4.肝病診斷市場主要廠商的市場佔有率是多少?
5.進入肝病診斷市場合適的型態和策略手段是什麼?
[194 Pages Report] The Liver Disease Diagnostics Market size was estimated at USD 9.94 billion in 2023 and expected to reach USD 11.09 billion in 2024, at a CAGR 12.76% to reach USD 23.05 billion by 2030.
The liver disease diagnostics market encompasses all technologies, products, and services dedicated to detecting and monitoring various liver conditions, including hepatitis, cirrhosis, liver cancer, and non-alcoholic fatty liver disease. The primary goal is to promote early detection, accurate staging, and effective management of liver-related diseases. The rising prevalence of liver diseases, increased awareness and preventive approaches, and improvements in healthcare infrastructure across various regions have necessitated the adoption of liver disease diagnostics solutions. Additionally, supportive government initiatives and funding for liver disease research and management accentuate the need for liver disease diagnostics. However, liver disease diagnostics faces challenges related to the high costs of advanced diagnostic tests, discrepancies in liver disease diagnostic standards, and limited accessibility in low-resource settings. Moreover, the lack of specific biomarkers for certain liver diseases and the risks associated with invasive diagnostic procedures can hinder growth. However, key players are exploring cutting-edge developments such as non-invasive imaging technologies and biomarker discovery to circumvent technical and safety complications. Furthermore, the increasing integration of AI and ML in diagnostics, which promises enhanced accuracy and predictive analytics, also opens up new avenues for growth. Personalized medicine and genomics are also gaining traction, offering the potential for tailored diagnostic and therapeutic approaches.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 9.94 billion |
Estimated Year [2024] | USD 11.09 billion |
Forecast Year [2030] | USD 23.05 billion |
CAGR (%) | 12.76% |
Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis
A liver biopsy is a process that involves the removal of a small section of liver tissue, which is then examined under a microscope. Biopsies can be crucial in diagnosing certain liver diseases that are not detectable through blood tests or imaging and in determining the degree of liver damage. Biopsies are often recommended when it is necessary to analyze the severity of liver damage in chronic conditions such as hepatitis C or to diagnose unexplained liver abnormalities. Endoscopy for liver diagnostics most often refers to a procedure known as endoscopic retrograde cholangiopancreatography, which is used to examine the bile ducts. It can identify blockages or abnormalities connected with liver diseases. Endoscopy is typically used when there is a suspicion of diseases that affect the bile ducts or when there's a need to extract bile duct stones. Imaging techniques include ultrasound, computed tomography scan, magnetic resonance imaging, and other modalities that provide detailed pictures of the liver and can help diagnose conditions like fatty liver, tumors, and cirrhosis. Imaging is the first line of non-invasive diagnostic techniques often used when there's a need for a visual assessment of the liver structure and detection of masses. Laboratory tests help in the diagnosis of liver diseases through the analysis of blood samples. Common tests include liver enzyme tests such as the alanine transaminase (ALT) test, aspartate aminotransferase (AST) test, bilirubin tests, albumin tests, clotting tests, and viral hepatitis tests. Laboratory tests are usually the first step in diagnosing liver disease and are used for routine screening, monitoring of disease progression, and evaluating treatment efficacy.
End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure
Hospitals represent a significant end-user for liver disease diagnostics. They are typically equipped with advanced diagnostic equipment and staffed by specialized healthcare professionals. Patients with liver diseases often require immediate and comprehensive care, which hospitals are usually able to provide. This includes a series of diagnostic tests such as blood tests, imaging, and biopsies to confirm the diagnosis of conditions such as hepatitis, cirrhosis, or liver cancer. The need-based preference for hospitals is generally high due to their ability to offer a full spectrum of services from diagnosis to treatment, including emergency care, surgery, and post-operative follow-ups. The integration of diagnostic services with therapeutic care is a compelling reason for patients to choose hospital-based diagnostics. Laboratories, either standalone or those associated with clinics, specialize in the analysis of blood and tissue samples to detect liver abnormalities. Compared to hospitals, laboratories may offer more convenient locations and quicker processing times for diagnostic tests, which can result in faster results for patients and physicians. Laboratories primarily cater to the need for routine screening and blood work required for the diagnosis and monitoring of liver diseases.
Regional Insights
The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement policies for various disease conditions, thereby fuelling the growth in liver disease diagnostics. Innovations in non-invasive imaging techniques and bio-marker identification are areas where significant investments and patent applications are seen. Initiatives such as the American Liver Foundation's efforts to improve liver health reflect the sector's proactive approach. The European Union displays diverse consumer behavior due to varying healthcare systems and economic capabilities across member countries. However, the adoption of the European Association for the Study of the Liver Clinical Practice Guidelines is a key factor in standardizing liver disease diagnostics. Increased R&D expenditure and multinational collaborations, such as those within the EU Horizon 2020 program, showcase the dynamic environment of innovation in the region. APAC region shows a burgeoning need for liver disease diagnostics due to the growing prevalence of liver-related disorders, growing awareness about liver health, and government initiatives to expand healthcare facilities to marginalized communities. The adoption of digital healthcare services and solutions is also gaining traction in the APAC region, which could create new avenues of growth for the industry.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Liver Disease Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Liver Disease Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Disease Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Liver Disease Diagnostics Market?
4. What is the market share of the leading vendors in the Liver Disease Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Liver Disease Diagnostics Market?